Collegium Pharmaceutical, Inc
COLL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001267565
No open-market purchases or sales by Collegium Pharmaceutical, Inc insiders were filed in the last 90 days; 279 institutions reported holding it in 13F filings for Q2 2026, worth $1.42B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Collegium Pharmaceutical, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Collegium Pharmaceutical, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Santini Gino | Director | 112,483 | Jun 10, 2026 | 2 |
| Freund John Gordon | Director | 83,952 | May 20, 2026 | 2 |
| Bohlin Garen G | Director | 71,000 | May 18, 2026 | 2 |
| Lurker Nancy | Director | 26,758 | May 18, 2026 | 2 |
| Paya Carlos V | Director | 28,323 | May 18, 2026 | 1 |
| Balice-Gordon Rita J. | Director | 61,370 | May 18, 2026 | 2 |
| Glancy Donovan Michael | Director | 17,482 | May 18, 2026 | 1 |
| Dieter David | EVP & General Counsel | 68,231 | Apr 3, 2026 | 4 |
| Dreyer Scott | EVP & Chief Commercial Officer | 71,770 | Mar 5, 2026 | 3 |
| Karnani Vikram | President and CEO | 197,864 | Feb 12, 2026 | 2 |
| Smith Thomas B | EVP and Chief Medical Officer | 90,651 | Feb 12, 2026 | 1 |
| Tupper Colleen | EVP & Chief Financial Officer | 147,282 | Feb 12, 2026 | 2 |
| Fallon John A. | Director | 64,634 | Nov 14, 2025 | 1 |
| Rubric Capital Management LP | 10% Owner | 3,132,743Indirect | Aug 15, 2025 | 0 |
| Rosen David Efraim | 10% Owner | 3,132,743Indirect | Aug 15, 2025 | 0 |
| Kuhlmann Shirley R. | EVP and General Counsel | 108,137 | Mar 6, 2025 | 0 |
| Heffernan Michael Thomas | Director | 50,328 | Feb 12, 2025 | 0 |
| Melincoff Gwen A | Director | 52,468 | May 16, 2024 | 0 |
| McFarlane Neil F. | Director | 49,365 | May 16, 2024 | 0 |
| Ciaffoni Joseph | President and CEO | 444,867 | Feb 14, 2024 | 0 |
| Malamut Richard | EVP and Chief Medical Officer | 130,264 | Feb 14, 2022 | 0 |
| Fleming Alison B | EVP & Chief Technical Officer | 143,694 | Aug 12, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 21, 2022 (view filing) | Dec 19-21 | 2 days | Heffernan Michael ThomasDirector | SSale | −84.0K | $23.09 | −$1.94M | −75.0%28.0K after | 3 lots |
| Dec 21, 2022 (view filing) | Dec 19-21 | 2 days | Ciaffoni JosephPresident and CEO | SSale | −17.8K | $23.08 | −$411.8K | −6.6%251.2K after | 3 lots |
| Dec 14, 2022 (view filing) | Dec 12-13 | 2 days | Heffernan Michael ThomasDirector | SSale | −189.6K | $22.14 | −$4.20M | −87.1%28.0K after | 2 lots |
| Dec 5, 2022 (view filing) | Dec 1-2 | 4 days | Ciaffoni JosephPresident and CEO | SSale | −131.1K | $22.72 | −$2.98M | −32.8%269.1K after | 2 lots |
| Nov 30, 2022 (view filing) | Nov 28 | 2 days | Ciaffoni JosephPresident and CEO | SSale | −43 | $22.00 | −$946 | 0.0%323.5K after | |
| Nov 25, 2022 (view filing) | Nov 22 | 3 days | Ciaffoni JosephPresident and CEO | SSale | −65 | $22.00 | −$1.43K | 0.0%323.5K after | |
| Nov 22, 2022 (view filing) | Nov 18 | 4 days | Ciaffoni JosephPresident and CEO | SSale | −1.99K | $22.02 | −$43.8K | −0.6%323.5K after | |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Tupper ColleenEVP & Chief Financial Officer | SSale | −4.35K | $17.35 | −$75.5K | −4.6%90.3K after | |
| Sep 16, 2022 (view filing) | Sep 15 | 1 day | Kuhlmann Shirley R.EVP and General Counsel | SSale | −38.6K | $18.07 | −$697.3K | −26.1%109.5K after | |
| Aug 15, 2022 (view filing) | Aug 11 | 4 days | Kuhlmann Shirley R.EVP and General Counsel | SSale | −300 | $20.01 | −$6.00K | −0.2%148.1K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Ciaffoni JosephPresident and CEO | SSale | −76.1K | $18.47 | −$1.41M | −19.0%324.8K after | 2 lots |
| Feb 28, 2022 (view filing) | Feb 18 | 10 daysLate | Dreyer ScottEVP & Chief Commercial Officer | SSale | −10.6K | $21.61 | −$228.2K | −8.0%121.2K after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Dreyer ScottEVP & Chief Commercial Officer | SSale | −5.69K | $18.33 | −$104.4K | −6.9%77.0K after |